[Federal Register Volume 63, Number 201 (Monday, October 19, 1998)]
[Notices]
[Pages 55877-55878]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-27963]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Opportunities for Cooperative Research
and Development Agreements
National Cancer Institute: Opportunities for Cooperative Research
and Development Agreements (CRADAs) for the identification of analogues
of wnt ligands that bind a novel soluble Frizzled-related receptor
discovered at the National Cancer Institute (NCI) (the ``Technology'').
Wnt proteins act as inducing agents during embryogenesis and have been
implicated in the etiology of cancer. Frizzled proteins are integral
membrane proteins that recently were shown to function as receptors for
wnt signaling molecules. Currently, NCI has identified at least two
applications for this Technology: research product and drug screening.
The NCI is looking for a CRADA Collaborator with access to phage
display peptide libraries for analogue screening to develop this
Technology.
AGENCY: National Institutes of Health, PHS, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA,
15 U.S.C. Sec. 3710; Executive Order 12591 of April 10, 1987 as amended
by the National Technology Transfer and Advancement Act of 1995), the
National Cancer Institute (NCI) of the National Institutes of Health
(NIH) of the Public Health Service (PHS) of the Department of Health
and Human Services (DHSS) seeks one or more CRADAs with pharmaceutical
or biotechnology companies to develop this Technology.
Any CRADA for the biomedical use of this technology will be
considered. The CRADA would have an expected duration of one (1) to
five (5) years. The goals of the CRADA include the rapid publication of
research results and the timely commercialization of products,
diagnostics and treatments that result from the research. The CRADA
Collaborator will have an option to negotiate the terms of an exclusive
or nonexclusive commercialization license to subject inventions arising
under the CRADA.
ADDRESSES: Proposals and questions about these CRADA opportunities may
be addressed to Vasant T. Gandhi, Technology Development and
Commercialization Branch, National Cancer Institute, Executive Plaza
South, Room 450, 6120 Executive Blvd., Rockville, MD 20852. Telephone:
(301) 496-0477, Facsimile: (301) 402-2117. Background information,
including abstracts and reprints, is available. In addition, pertinent
information not yet publicly disclosed may be obtained under a
confidential disclosure agreement.
EFFECTIVE DATE: In view of the high interest for developing the
Technology, interested parties should notify the NCI Technology
Development and Commercialization Branch in writing no later than
November 18, 1998. Respondents will then be provided an additional
thirty (30) days for submitting formal CRADA proposals.
SUPPLEMENTARY INFORMATION: A novel Frizzled-related soluble receptor
has been expressed recombinantly and used in an ELISA format to bind
protein ligand. The NCI Laboratory of Cellular and Molecular Biology
(LCMB) would like to identify peptide analogs of a natural wnt ligand
by using the recombinant receptor to pan phage display peptide
libraries. To this end, the NCI LCMB would like to establish a CRADA
with a biotechnology company possessing phage display peptide libraries
and interested in participating in the screening effort. Analogs
identified in this manner would be tested for agonist or antagonist
activity, and might serve as prototypes of reagents capable of
modulating wnt signaling associated receptor pathways.
The role of the National Cancer Institute in this CRADA will
include, but not be limited to:
1. Providing intellectual, scientific, and technical expertise and
experience to the research project.
2. Planning research studies and interpreting research results.
3. Publishing research results.
The role of the CRADA Collaborator may include, but not be limited
to:
1. Possession of a phage display peptide library.
2. Planning research studies and interpreting research results.
3. Providing support for onging CRADA-related research in the
development of the particular application of the Technology.
(a) Financial support to facilitate scientific goals;
(b) Technical or financial support for further design of
applications.
[[Page 55878]]
4. Publishing research results.
Selection criteria for choosing the CRADA Collaborator may include,
but not be limited to:
1. The ability to collaborate with NCI on further research and
development of this Technology. This ability can be demonstrated
through experience and expertise in this or related areas of Technology
indicating the ability to contribute intellectually to ongoing research
and development.
2. The ability to collaborate with NCI on further research and
development of this Technology. This ability can be demonstrated
through experience and expertise in this or related areas of Technology
indicating the ability to contribute intellectually to ongoing research
and development.
3. The demonstration of adequate resources to perform the research,
development and commercialization of this technology (e.g. facilities,
personnel and expertise) and accomplish objectives according to an
appropriate timetable to be outlined in the CRADA Collaborator's
proposal.
4. The willingness to commit best effort and demonstrated resources
to the research, development and commercialization of this Technology.
5. The demonstration of expertise in the commercial development,
production, marketing and sales of products related to this area of
Technology.
6. The level of financial support the CRADA Collaborator will
provide for CRADA-related Government activities.
7. The willingness to cooperate with the National Cancer Institute
in the timely publication of research results.
8. The agreement to be bound by the appropriate DHHS regulations
relating to human subjects, and all PHS policies relating to the use
and care of laboratory animals.
9. The willingness to accept the legal provisions and language of
the CRADA with only minor modifications, if any. These provisions
govern the equitable distribution of patent rights to CRADA inventions.
Generally, the rights of ownership are retained by the organization
that is the employer of the inventor, with (1) the grant of a license
for research and other Government purposes to the Government when the
CRADA Collaborator's employee is the sole inventor, or (2) the grant of
an option to elect an exclusive or nonexclusive license to the CRADA
Collaborator when the Government employee is the sole inventor.
Dated: October 8, 1998.
Kathleen Sybert,
Acting Director, Technology Development and Commercialization Branch,
National Cancer Institute, National Institutes of Health.
[FR Doc. 98-27963 Filed 10-16-98; 8:45 am]
BILLING CODE 4140-01-M
